The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus recommends molecular sequencing and biomarker testing for patients with early-stage NSCLC to guide perioperative treatment selection while currently, the NCCN recommends testing only for EGFR mutations and ALK fusions.5,13. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.